BioNTech SE
NASDAQ:BNTX

Watchlist Manager
BioNTech SE Logo
BioNTech SE
NASDAQ:BNTX
Watchlist
Price: 113.13 USD 4.53% Market Closed
Market Cap: 27.3B USD
Have any thoughts about
BioNTech SE?
Write Note
Section:
 

Relative Value

The Relative Value of one BNTX stock under the Base Case scenario is 33.33 USD. Compared to the current market price of 113.13 USD, BioNTech SE is Overvalued by 71%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BNTX Relative Value
Base Case
33.33 USD
Overvaluation 71%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

9.6
P/S
P/S
Price to Sales
9.6
vs History
11
vs Industry
56
Median 3Y
2.9
Median 5Y
2.3
Industry
7.7
Forward
9.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
1
Median 3Y
3.7
Median 5Y
3.4
Industry
22.7
Forward
-35.5
More Details
8.7
P/OCF
P/OCF
Price to OCF
8.7
vs History
11
vs Industry
14
Median 3Y
4
Median 5Y
2.8
Industry
21.6
More Details
11.3
P/FCFE
P/FCFE
Price to FCFE
11.3
vs History
15
vs Industry
11
Median 3Y
4.5
Median 5Y
3.2
Industry
25.2
More Details
1.4
P/B
P/B
Price to Book Value
1.4
vs History
69
vs Industry
62
Median 3Y
1.4
Median 5Y
2.3
Industry
2.5
More Details
3.2
EV/S
EV/S
Enterprise Value to Sales
3.2
vs History
20
vs Industry
77
Median 3Y
1.3
Median 5Y
1.2
Industry
7.7
Forward
3.3
More Details
3.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.8
vs History
20
vs Industry
74
Median 3Y
1.5
Median 5Y
1.5
Industry
9
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
12
Median 3Y
1.6
Median 5Y
1.8
Industry
4.2
Forward
-7.6
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
11
Median 3Y
1.7
Median 5Y
1.4
Industry
4.1
Forward
-8.2
More Details
2.9
EV/OCF
EV/OCF
Enterprise Value to OCF
2.9
vs History
20
vs Industry
22
Median 3Y
1.6
Median 5Y
0.9
Industry
5.7
More Details
3.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
3.7
vs History
17
vs Industry
17
Median 3Y
1.7
Median 5Y
1
Industry
3.6
More Details
2.2
EV/IC
EV/IC
Enterprise Value to IC
2.2
vs History
63
vs Industry
65
Median 3Y
1.8
Median 5Y
2.4
Industry
4.6
More Details

Multiples Across Competitors

BNTX Competitors Multiples
BioNTech SE Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DE
BioNTech SE
NASDAQ:BNTX
26.9B USD 9.6 -51.2 -16.7 -11.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 083 264.3 -181 004.1 -219 796.6 -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 5.6 61.5 15.3 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 10.9 -241.6 24 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 4 891.9 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 849.9 -472 -514.1 -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 5.9 17.8 16.2 18
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.7 -53
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.5 -129.9 -104.5 -76.2
P/E Multiple
Earnings Growth
DE
BioNTech SE
NASDAQ:BNTX
Average P/E: 208.3
Negative Multiple: -51.2 		N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
DE
BioNTech SE
NASDAQ:BNTX
Average EV/EBITDA: 17.2
Negative Multiple: -16.7 		N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
DE
BioNTech SE
NASDAQ:BNTX
Average EV/EBIT: 22.5
Negative Multiple: -11.9 		N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.2 N/A

See Also

Summary
BNTX intrinsic value, competitors valuation, and company profile.
DCF Valuation
BNTX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BNTX stock valuation using valuation multiples.
Wall Street Estimates
BNTX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BNTX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 201,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.